Amgen Inc. stock (US0311621009): shares little changed as investors digest recent earnings and drug pipeline updates

Amgen Inc. shares on Nasdaq traded roughly flat on 05/29/2026 as investors continued to assess the US biotech group’s latest quarterly results and updates across its drug portfolio, keeping the stock in focus for developments in the United States healthcare sector.

Amgen Inc. shares on the Nasdaq in the United States were little changed in recent trading as investors continued to weigh the large-cap biotech’s latest earnings release and developments across its drug pipeline, keeping attention on one of the best-known US-listed pharmaceutical names.

The stock most recently changed hands at around USD 300 on Nasdaq on 05/29/2026, leaving the US-based company broadly in line with recent levels after its latest quarterly report and product news flow, according to Nasdaq pricing data as of 05/29/2026.

For investors in the United States, Amgen remains a key component of the domestic healthcare and biotechnology space, and its stable share price performance in the wake of its recent results suggests the market is still digesting details from its most recent filings and conference calls.

From a German perspective, the stock is also tradable on venues such as Tradegate in euros, offering an additional access point for European investors who wish to gain exposure to the US biotech group via local trading infrastructure.

Beyond the immediate share price action, the company’s recent news cycle has been dominated by financial figures from its latest reported quarter, ongoing integration of acquired assets and a steady stream of updates on key therapies in areas such as oncology, inflammation and cardiovascular disease.

These moving parts together form the backdrop for the current trading range and help explain why the stock has not made a decisive move in either direction in the very latest sessions despite an active fundamental and pipeline story.

As of: 05/31/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Amgen
• Sector/industry: Biotechnology and biopharmaceuticals
• Headquarters/country: Thousand Oaks, United States
• Core markets: United States, Europe, Asia-Pacific and other international markets
• Key revenue drivers: Innovative therapies across oncology, inflammation, bone health, cardiovascular disease and other specialty indications
• Home exchange/listing venue: Nasdaq (AMGN)
• Trading currency: USD

Amgen Inc.: core business model

The company focuses on researching, developing, manufacturing and commercializing innovative biologic and small-molecule medicines that generate revenue primarily through sales of branded prescription drugs across a diversified portfolio of therapeutic areas.

Chart technicals and 52-week range

From a technical perspective, Amgen’s share price remains within its observed 52-week band on Nasdaq, with the stock having traded between roughly USD 230 and USD 320 over the past year depending on the precise measurement date used by the respective data providers.

This places the most recent level toward the upper half of that annual range, suggesting that while the stock has already staged a notable recovery from its lows, it has not yet consistently broken above the highest marks set during the period, leaving the chart in a broadly sideways-to-up configuration for now.

Conclusion

Amgen Inc. shares on Nasdaq in the United States are currently trading in a relatively stable fashion after the company’s latest reported results and ongoing product news, with the price sitting within its established 52-week range.

For investors, the combination of a steady chart profile and an active flow of earnings and pipeline updates means that the stock continues to be closely watched in the context of the broader US biotechnology and healthcare sector.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.